Navigation Links
Celebrex Appears Easier on Stomach for Arthritis Patients
Date:6/17/2010

Diclofenac plus proton pump inhibitor quadrupled risk of gastrointestinal damage, study found

THURSDAY, June 17 (HealthDay News) -- Patients who take the painkiller celecoxib for arthritis pain and inflammation are less likely to suffer gastrointestinal damage than those who take diclofenac plus omeprazole, a new study finds.

Celecoxib (Celebrex) is a cox-2 selective non-steroidal anti-inflammatory drug (NSAID), diclofenac (Voltaren) is a non-selective NSAID and omeprazole (Prilosec) is a proton pump inhibitor (PPI).

The study included 4,484 patients in 32 countries or territories who were randomly selected to receive either 200 milligrams (mg) of celecoxib twice a day (2,238 patients) or 75 mg of diclofenac slow-release plus 20 mg of omeprazole (2,246 patients) once a day.

Patients taking diclofenac plus omeprazole were more than four times more likely to suffer upper or lower gastrointestinal damage than celecoxib patients -- 3.8 percent versus 0.9 percent, respectively.

The findings, which were released online June 17 in advance of publication in a future print issue of The Lancet, should prompt a review of approaches used to reduce the risk of NSAID treatment, said the authors of the CONDOR study.

"Since guidelines recommend that selection of NSAID therapy be driven by consideration of both cardiovascular and gastrointestinal effects of treatment, CONDOR has provided new data relevant to patients requiring anti-inflammatory therapy who are at increased gastrointestinal but not increased cardiovascular risk. In this population, the gastrointestinal outcomes of a cox-2 selective NSAID were quite different to those of a non-selective NSAID plus a PPI," Francis Chan of Prince of Wales Hospital, Hong Kong Special Administrative Region, China, and Jay Goldstein of the University of Illinois at Chicago, and colleagues wrote.

"Further understanding of the cardiovascular outcomes of these two strategies requires the results of ongoing trials that have been designed directly to address that important clinical question. The findings of the CONDOR trial should encourage guideline committees to review their treatment recommendations for arthritis patients," the researchers concluded.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about arthritis.



-- Robert Preidt



SOURCE: The Lancet, news release, June 17, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Can Celebrex prevent cancer-causing colon polyps?
2. Celebrex Might Thwart Inherited Skin Cancers
3. NAMI Medical Director Honored with APA Patient Advocacy Award; Appears in CNN Health and Huffington Post Columns
4. Taking Flu Drugs While Pregnant Appears to Be Safe: Study
5. Hospitalization Appears to Help Personality Disorder Patients
6. How health care is paid for appears to impact outcome
7. Protein Appears Key to Intestinal Balance
8. Medication appears well-tolerated, beneficial in Huntingtons disease patients
9. Ashworth College Instructor Dr. Nicole Detling Miller Appears on Colbert Report
10. Brain Damage: NFL ‘Gets It,' American Society of Anesthesiologists Still Appears ‘Asleep'
11. Traumatic brain injuries: Motor deficits can persist even after what appears to be a full recovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex Appears Easier on Stomach for Arthritis Patients
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology: